Haemonetics reports Q3 adjusted EPS $1.19, consensus $1.17

Reports Q3 revenue $348.5M, consensus $352.88M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Our record third-quarter margins demonstrate our long-range plan is successfully driving profitable growth. We are gaining share, driving meaningful value through our differentiated technologies and strengthening our leadership as we navigate external market challenges, while accelerating portfolio evolution for further margin expansion. We are confident in the foundation we are building for sustained long-term growth across our business.”